Cancer Pain - Pipeline Review, Q1 2011

Description: Cancer Pain - Pipeline Review, Q1 2011

Summary

Global Markets Direct's, 'Cancer Pain - Pipeline Review, Q1 2011', provides an overview of the Cancer Pain therapeutic pipeline. This report provides information on the therapeutic development for Cancer Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Pain. 'Cancer Pain - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cancer Pain.
- A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cancer Pain pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cancer Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Cancer Pain therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cancer Pain Overview
Therapeutics Development
An Overview of Pipeline Products for Cancer Pain
Cancer Pain Therapeutics under Development by Companies
Cancer Pain Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Cancer Pain Therapeutics - Products under Development by Companies
Genzyme Corporation
Abbott Laboratories
Shionogi & Co., Ltd.
Ipsen S.A.
AKELA Pharma Inc.
Archimedes Pharma Limited
Aphios Corporation
AcelRx Pharmaceuticals, Inc.
Nippon Kayaku Co., Ltd.
Nippon Shinyaku Co., Ltd.
GW Pharmaceuticals plc
Mundipharma International Limited
Diamyd Medical AB
ProStrakan Group plc
BioAlliance Pharma SA
Labtec GmbH
INSYS Therapeutics, Inc.
ImmuPharma Plc
WEX Pharmaceuticals Inc.
QRxPharma Limited
Xenome Ltd.
EUSA Pharma, Inc.
Cancer Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Sativex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Abstral - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludara - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fentanyl TAIFUN - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tectin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OVF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-811717 - Drug Profile
Product Description
Mechanism of Action
Fentanyl Sublingual Spray - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NS-315 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxycodone hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GW-2000-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sufentanil Transdermal System - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PecFent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TK-642 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Methylprednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methadone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cancer Pain Therapeutics - Discontinued Products
Cancer Pain - Featured News
Nov 23, 2010: GW Pharmaceuticals' Sativex Enters Phase III Clinical Program In Cancer Pain
Oct 01, 2010: AcelRx Completes End-Of-Phase II Meeting With FDA For ARX-02 For Treatment Of Cancer Pain
Sep 28, 2010: WEX Announces Update On Interim Analysis Of TEC-006 Clinical Trial With Tetrodotoxin
Sep 01, 2010: Afferent Reports Data Supporting Use Of P2X3 Antagonists In Reducing Bone Cancer Pain
Sep 01, 2010: Archimedes Pharma Receives European Marketing Authorization For PecFent For Treatment Of Cancer Pain
Aug 25, 2010: WEX To Present Clinical Data On Tetrodotoxin At 13th World Congress on Pain
Jun 25, 2010: Archimedes Pharma Receives CHMP Positive Opinion For PecFent For Treatment Of Breakthrough Cancer Pain
May 25, 2010: AcelRx Announces Positive Phase II Results Of ARX-02 Sufentanil NanoTab For Treatment Of Cancer Breakthrough Pain
May 10, 2010: Onsolis approved in Canada
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Cancer Pain, Q1 2011
Products under Development for Cancer Pain – Comparative Analysis, Q1 2011
Comparative Analysis by Late Stage Development, Q1 2011
Comparative Analysis by Mid Clinical Stage Development, Q1 2011
Comparative Analysis by Early Clinical Stage Development, Q1 2011
Comparative Analysis by Pre-Clinical Stage Development, Q1 2011
Genzyme Corporation, 2011
Abbott Laboratories, 2011
Shionogi & Co., Ltd., 2011
Ipsen S.A., 2011
AKELA Pharma Inc., 2011
Archimedes Pharma Limited, 2011
Aphios Corporation, 2011
AAcLPharmaceuticals, Inc., 2011
Nippon Kayaku Co., Ltd., 2011
Nippon Shinyaku Co., Ltd., 2011
GW Pharmaceuticals plc, 2011
Mundipharma International Limited, 2011
Diamyd Medical AB, 2011
ProStrakan Group plc, 2011
BioAlliance Pharma SA, 2011
Labtec GmbH, 2011
INSYS Therapeutics, Inc., 2011
Immupharma Plc, 2011
WEX Pharmaceuticals Inc., 2011
QRxPharma Limited, 2011
Xenome Ltd., 2011
EUSA Pharma, Inc., 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Discontinued Products

List of Figures
Number of Products under Development for Cancer Pain, Q1 2011
Products under Development for Cancer Pain – Comparative Analysis, Q1 2011
Products under Development by Companies, Q1 2011
Products under Investigation by Universities/Institutes, Q1 2011
Late Stage Products, Q1 2011
Mid Clinical Stage Products, Q1 2011
Early Clinical Stage Products, Q1 2011
Pre-Clinical Stage Products, Q1 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Combination Products, Q1 2011
Assessment by Route of Administration, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Assessment by Stage and Molecule Type, Q1 2011

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1590130/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Cancer Pain - Pipeline Review, Q1 2011
Web Address: http://www.researchandmarkets.com/reports/1590130/
Office Code: SCD2STPA

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp